Download PDF
Thromb Haemost 1998; 79(03): 554-556
DOI: 10.1055/s-0037-1614943
Review Articles
Schattauer GmbH

Thrombomodulin Levels during Normal Pregnancy, at Delivery and in the Postpartum: Comparison with Tissue-type Plasminogen Activator and Plasminogen Activator Inhibitor-1

de P. Moerloose
1   Unité d’Hémostase, Gynécologie-Obstétrique, Hôpital Cantonal Universitaire, Genève, Switzerland
,
N. Mermillod
1   Unité d’Hémostase, Gynécologie-Obstétrique, Hôpital Cantonal Universitaire, Genève, Switzerland
,
J. Amiral
2   Serbio, Gennevilliers, France
,
G. Reber
1   Unité d’Hémostase, Gynécologie-Obstétrique, Hôpital Cantonal Universitaire, Genève, Switzerland
› Author Affiliations
Further Information

Publication History

Received 29 July 1997

Accepted 16 October 1997

Publication Date:
07 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Some studies suggest that soluble thrombomodulin (TM) could be used as a marker of preeclampsia or eclampsia. However little is known about the sequential changes of TM during the course of normal pregnancy.

Levels of TM were determined in 100 women with uneventful pregnancies. Samples (n = 394) were divided into five study intervals, three during pregnancy, one at delivery and one three days postpartum.

As compared with TM levels (median 34.3 ng/ml, range 17.6-61) of a control group of 60 healthy non-pregnant women, TM levels were shown to increase throughout pregnancy, median (and range) values being respectively 38.5 (17.6-72.7) from 11 to 20 weeks, 45.2 (22.6-75.2) from 21 to 30 weeks and 54.3 (25.1-114.5) ng/ml from 31st week to delivery. One hour after delivery TM levels were still elevated and dropped three days postpartum to 40.5 (20.9-79.4) ng/ml. The increase of TM levels was correlated with those of tissue-type plasminogen activator and plasminogen activator inhibitor-1 antigens. The large overlap in TM levels between the study periods seems to preclude a clinical use of TM based on reference values from a control group. Our data suggest that it would be more appropriate to take into account TM baseline values in a given woman to examine her TM increase during pregnancy.

 

  • References

  • 1 Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-6.
    PubMedSearch in Google Scholar
  • 2 Ishii H, Majerus PW. Thrombomodulin is present in plasma and urine. J Clin Invest 1985; 76: 2178-81.
    CrossrefPubMedSearch in Google Scholar
  • 3 Boffa M-C. Considering cellular thrombomodulin distribution and its modulating factors can falicitate the use of plasma thrombomodulin as a reliable endothelial marker. Haemostasis 1996; Suppl (04) 233-43.
    PubMedSearch in Google Scholar
  • 4 Minakami H, Takahashi T, Izumi A, Tamada T. Increased levels of plasma thrombomodulin in preeclampsia. Gynecol Obstet Invest 1993; 36: 208-10.
    CrossrefPubMedSearch in Google Scholar
  • 5 Hsu C-D, Copel J, Hong S-F, Chan DW. Thrombomodulin levels in preeclampsia, gestational hypertension, and chronic hypertension. Obstet Gynecol 1995; 86: 897-9.
    CrossrefPubMedSearch in Google Scholar
  • 6 Bontis J, Vavilis D, Agoratos T, Zournatzi V, Konstantinidis T, Tagou K. Maternal plasma level of thrombomodulin is increased in mild preeclampsia. Eur J Obstet Gynecol 1995; 60: 139-41.
    CrossrefPubMedSearch in Google Scholar
  • 7 Shaarawy M, El Didy H. Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia. Int J Gynecol Obstet 1996; 55: 135-9.
    CrossrefPubMedSearch in Google Scholar
  • 8 Hellgern M, Blombäck M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. Gynecol Obstet Invest 1981; 12: 141-54.
    CrossrefPubMedSearch in Google Scholar
  • 9 Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in pregnancy. Thromb Haemost 1984; 52: 176-82.
    Thieme ConnectPubMedSearch in Google Scholar
  • 10 Kruithof EKO, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987; 69: 460-6.
    PubMedSearch in Google Scholar
  • 11 Mackinnon S, Walker ID, Davidson JF, Walker JJ. Plasma fibrinolysis during and after normal childbirth. Br J Haematol 1987; 65: 339-42.
    CrossrefPubMedSearch in Google Scholar
  • 12 Estelles A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe pre-eclampsia. Blood 1989; 74: 1332-8.
    PubMedSearch in Google Scholar
  • 13 Bonnar J, Daly L, Sheppard BL. Changes in the fibrinolytic system during pregnancy. Semin Thromb Haemostas 1990; 16: 221-9.
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 van Wersh JW, Ubachs JM. Blood coagulation and fibrinolysis during pregnancy. Eur J Clin Chem Clin Biochem 1991; 29: 45-50.
    PubMedSearch in Google Scholar
  • 15 Bremme K, Ostlund E, Almqvist I, Heinonen K, Blombäck M. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet Gynecol 1992; 80: 132-7.
    PubMedSearch in Google Scholar
  • 16 Reith A, Booth N, Moore NR, Cruickshank DJ, Bennett B. Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, preeclampsia and hydatidiform mole. Br J Obstet Gynecol 1993; 100: 370-4.
    CrossrefPubMedSearch in Google Scholar
  • 17 Halligan A, Bonnar J, Sheppard B, Darling M, Walshe J. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. Br J Obstet Gynecol 1994; 101: 488-92.
    CrossrefPubMedSearch in Google Scholar
  • 18 Sorensen JD, Secher NJ, Jespersen J. Perturbed (procoagulant) endothelium and deviations within the fibrinolytic system during the third trimester of normal pregnancy. Acta Obstet Gynecol Scand 1995; 74: 257-61.
    CrossrefPubMedSearch in Google Scholar
  • 19 Amiral J, Adam M, Mimilia F, Larrivaz I, Chambrette B, Boffa MC. Design and validation of a new immunoassay for soluble forms of thrombomodulin and studies in plasma. Hybridoma 1994; 13: 205-13.
    CrossrefPubMedSearch in Google Scholar
  • 20 Ballegeer V, Mombaerts P, Declerck PJ, Spitz B, Van Assche FA, Collen D. Fibrinolytic response to venous occlusion and fibrin fragment D-dimer levels in normal and complicated pregnancy. Thromb Haemost 1987; 58: 1030-2.
    Thieme ConnectPubMedSearch in Google Scholar
  • 21 Cadroy Y, Grandjean H, Pichon J, Desprats R, Berrebi A, Fournié A, Boneu B. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynecol 1993; 100: 416-20.
    CrossrefPubMedSearch in Google Scholar
  • 22 Wright JG, Cooper P, Astedt B, Lecander I, Wilde JT, Preston FE, Greaves M. Fibrinolysis during normal human pregnancy: complex interrelationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time. Br J Haematol 1988; 69: 253-8.
    CrossrefPubMedSearch in Google Scholar